2023 Tuberculosis Drug Discovery and Development Gordon Research Conference and Gordon Research Seminar

2023结核病药物发现与开发戈登研究大会暨戈登研究研讨会

基本信息

批准号：
10675238
负责人：
Dirk Schnappinger
金额：
$ 0.6万
依托单位：
GORDON RESEARCH CONFERENCES
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-07-11 至 2023-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10675238
关键词：
Address Architecture Area Automobile Driving Bacterial Infections Biology Budgets COVID-19 Cessation of life Chemicals Clinical Clinical Trials Clinical Trials Design Collaborations Communicable Diseases Communities Complex Country Coupled Data Development Disclosure Disease Drug Combinations Drug Industry Drug resistance Drug resistance in tuberculosis Environment Evaluation Face Faculty Fostering Funding Agency Geography Goals Growth Health Priorities Hour Human Income Industrialization Infectious Agent Injectable Institution International Lead Learning Leisures Location Mentors Methods Multidrug-Resistant Tuberculosis Mycobacterium tuberculosis Oral Participant Performance Pharmaceutical Preparations Pharmacologic Substance Play Postdoctoral Fellow Privatization Regimen Research Research Personnel Science Scientist Series Site Socialization Spain Speed Structure Students Technology Time Training Translational Research Tuberculosis Underrepresented Minority United States National Institutes of Health Woman career career development design drug development drug discovery drug efficacy drug-sensitive early-career faculty fighting global health improved innovation insight meetings new technology next generation novel novel strategies novel therapeutics pandemic disease premature prevent programs research study side effect success symposium tuberculosis chemotherapy tuberculosis drugs tuberculosis treatment

Address Architecture Area Automobile Driving Bacterial Infections Biology Budgets COVID-19 Cessation of life Chemicals Clinical Clinical Trials Clinical Trials Design Collaborations Communicable Diseases Communities Complex Country Coupled Data Development Disclosure Disease Drug Combinations Drug Industry Drug resistance Drug resistance in tuberculosis Environment Evaluation Face Faculty Fostering Funding Agency Geography Goals Growth Health Priorities Hour Human Income Industrialization Infectious Agent Injectable Institution International Lead Learning Leisures Location Mentors Methods Multidrug-Resistant Tuberculosis Mycobacterium tuberculosis Oral Participant Performance Pharmaceutical Preparations Pharmacologic Substance Play Postdoctoral Fellow Privatization Regimen Research Research Personnel Science Scientist Series Site Socialization Spain Speed Structure Students Technology Time Training Translational Research Tuberculosis Underrepresented Minority United States National Institutes of Health Woman career career development design drug development drug discovery drug efficacy drug-sensitive early-career faculty fighting global health improved innovation insight meetings new technology next generation novel novel strategies novel therapeutics pandemic disease premature prevent programs research study side effect success symposium tuberculosis chemotherapy tuberculosis drugs tuberculosis treatment

展开

项目摘要

ABSTRACT This application seeks support for the 2023 Tuberculosis (TB) Drug Discovery & Development Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held in at the Rey Don Jaime Grand Hotel in Castelldefels, Spain from July 22-23 and July 23 – 28, 2023. This will be the eleventh GRC on TB Drug discovery (with the first being held in 2001 and thereafter on a biennial basis) and the fifth GRS associated with this GRC. For more than 20 years this conference series has held a unique place in the global portfolio of TB research conferences. For many years it has been oversubscribed, been rated above average by more than 70% of attendees and received a high-performance rating in the GRC Evaluation. Among the factors that makes this conference series stand out are its rigorous focus on TB drug development, the emphasis on presentation of unpublished data (enabled by the strictly enforced rules against recording or photographing of presentations), the disclosure of novel hit and lead compounds, the large fraction of attendees from the pharmaceutical industry, and the well-attended networking sessions. The overall theme for this GRC is “Leads, technologies and clinical trials for new TB drug regimens”. The conference will discuss and disclose recently developed lead molecules as well as new technologies and approaches to clinical trials, debate how recent insight into TB biology and performance of clinical drug combinations may facilitate identifying leads and improving regimens, review how new technologies and trial innovations can identify improved drug regimens, and discuss how to capitalize on successes in other disease areas. The focus of this conference is thus quite different from the most recent conference in this series, which centered around treatment shortening and was held in 2019. The GRC and associated GRS foster an environment wherein which researchers are encouraged to share cutting edge unpublished data and exchange ideas between both established and young investigators and trainees hereby promoting career development for all attendees. The GRC will include a “Power Hour”, an optional gathering for all meeting participants to address the challenges underrepresented minorities and women face in science and to support their professional growth. Both the GRC and the GRS programs will reflect the diversity of the scientists in the field with an aim of strong representation of women, underrepresented minorities, and international scientists. GRCs are unique in facilitating multiple opportunities for informal interactions between researchers from different sectors, geographies, and career stages, often resulting in exchanges leading to new collaborations. In this pandemic era, such opportunities have become rare and thus even more important to driving forward innovation in research.

抽象的该申请寻求支持2023结核病（TB）药物发现与开发Gordon Research 会议（GRC）和戈登研究研讨会（GRS）将在Rey Don Jaime Grand Hotel举行西班牙Castelldefels，从7月22日至23日至2023年7月23日至28日。这将是TB毒品发现的第十一个GRC （首次在2001年及其两年期举行）和与此GRC相关的第五个GRS。 20多年来，该会议系列在TB Research的全球投资组合中占据了独特的位置会议。多年来，它被超额认购，被评为平均水平高于平均水平的70％以上与会者并在GRC评估中获得了高性能评级。在使这个的因素中会议系列引人注目的是对结核病药物开发的严格关注，重点是未发表的数据（由严格执行的规则启用，反对记录或摄影的演示文稿），披露新型命中和铅化合物的披露，是制药行业的大量参与者，以及受人尊敬的网络会议。该GRC的总体主题是“新的结核病药物方案的领导者，技术和临床试验”。会议将讨论并披露最近开发的铅分子以及新技术以及临床试验的方法，争论最近对结核病生物学和临床药物表现的见解组合可能有助于识别潜在客户并改善方案，回顾新技术和试验如何创新可以确定改善的药物方案，并讨论如何利用其他疾病的成功区域。因此，这次会议的重点与本系列的最新会议大不相同，以治疗缩短为中心，于2019年举行。 GRC和相关的GRS促进了一个鼓励研究人员分享的环境最先进的数据和年轻调查员之间的未发表的数据和交换思想受训者在此促进所有与会者的职业发展。 GRC将包括一个“力量时光”，一个所有会议参与者的可选聚会，以应对代表性不足的少数民族和妇女的挑战面对科学并支持其专业成长。 GRC和GRS程序都将反映该领域的科学家的多样性，目的是强烈代表妇女，代表性不足的少数民族，和国际科学家。 GRC在促进非正式互动的多种机会方面是独一无二的在不同部门，地理和职业阶段的研究人员之间，通常会导致交流导致新的合作。在这个大流行时代，这样的机会变得罕见，因此更多对于推动研究的前进创新很重要。